The value of the company depends on several decisions the management makes. These could be license or build, dilutive or non-dilutive funding, how much money to raise and its impact and so on. Farmantra’s  report provided helpful recommendations on both scientific and business aspects i.e. what all steps ImmunOs should consider to create value generated by the assets

They used three  I-O experts to triangulate the views with their internal team to develop the narrative,provide external insights on ImmunOs’ products and build a credible narrative both scientifically and financially.

We recommend Farmantra’s services.

Farmantra has helped us to evaluate the market potential and value of our new drug aimed for treatment of pulmonary hypertension. We are truly impressed by their work which they manage to deliver in a very efficient way and under stressed condition. Farmantra has also provided excellent advice on how to best capitalize our company and their reports has been appreciated by our investors. We highly recommend Farmantra.

“Farmantra has an intelligent proactive team able to quickly and accurately understand the needs of a biotechnology company, while at the same time offer seriousness, confidence and security. Having the opportunity to work with someone of the caliber of Farmantra is a true privilege”

Farmantra was assigned the challenging task of evaluating the strategic path Bionanoplus should take as we were operational in several sectors and areas. Farmantra team along with their experts did an excellent job in doing the following:

– Segregating short and long term strategies

– Identifying areas where Bionanoplus should focus on based on resources and capabilities we have

– Advising on right capital structure by assessing the value creation if we raise equity vs if we do not

– Focusing on areas and expertise that could create long term value for the shareholders

In sum, their analysis allowed us to make decisions and this is what any CEO needs to make especially in our life sciences sector that is beset with several risks and uncertainties. If you are looking at getting a high quality analysis on your strategic considerations with a financial perspective, go for it.

Farmantra did a great job in profesionalizing our financial plan. Amongst their work were, for example, very strong market studies, detailed risk simulations, what assets we should prioritize, a strong financing strategy, etc.. Thanks to Farmantra, we have a very good roadmap to maximise the company’s value. Their work has already helped us to pass a financial due diligence. In summary, we highly recommend Farmantra for any work related to Finance.

In order to outlicense our pro-biotic product AB-Life, Farmantra was chosen by our management team for the Indian market. We are pleased to say that they not only explored Indian market but also other markets such as Egypt , Bangladesh etc.

Farmantra delivered excellent results with a very high standard of professionalism. Their approach not only speaks of their well-developed skills but also of their ability to identify and overcome key barriers to the success of the project. Without a doubt we will use their services again for future ventures.

Last year, we decided to work on internationalization of Xcelia, Division of Advanced Therapies Blood and Tissue Bank of Barcelona. After analyzing various strategic options, India was chosen to be one of the countries to explore.

Farmantra was unanimously recommended by several professionals for their professionalism, knowledge of Indian markets, strong management team, pro-activeness and cultural adaptability to India and Spain.

Today, after working together with Farmantra for many months since they accepted the challenging project, we are dealing with real potential success, discussing with several potential candidates for licensing /co-development. During this time, progress has been steady, efficient, professional and above all honest.

We hope to celebrate the success of this project very soon.